{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:03:25Z","timestamp":1784822605060,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00973-5","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:58:53Z","timestamp":1781603933000},"page":"2011-2026","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Economic Impact of Cumulative Metabolic Comorbidity Burden in Schizophrenia: A Claims-Based Analysis of Medical Costs in the United States"],"prefix":"10.1007","volume":"15","author":[{"given":"Xue","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3999-2281","authenticated-orcid":false,"given":"Seth C.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8448-5663","authenticated-orcid":false,"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivanshu","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"973_CR1","unstructured":"World Health Organization. Schizophrenia [Fact sheet]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schizophrenia. (Accessed Oct 27, 2025)."},{"issue":"3","key":"973_CR2","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/s41380-024-02792-2","volume":"30","author":"H Lee","year":"2025","unstructured":"Lee H, Lee JH, Lee S, Lim JS, Kim HJ, Park J, et al. Comorbid health outcomes in patients with schizophrenia: an umbrella review of systematic reviews and meta-analyses. Mol Psychiatry. 2025;30(3):1127\u201337. https:\/\/doi.org\/10.1038\/s41380-024-02792-2.","journal-title":"Mol Psychiatry"},{"issue":"4","key":"973_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","volume":"4","author":"C Hjorthoj","year":"2017","unstructured":"Hjorthoj C, Sturup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295\u2013301. https:\/\/doi.org\/10.1016\/S2215-0366(17)30078-0.","journal-title":"Lancet Psychiatry"},{"key":"973_CR4","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796023000045","volume":"32","author":"S Ali","year":"2023","unstructured":"Ali S, Santomauro D, Ferrari AJ, Charlson F. Schizophrenia as a risk factor for cardiovascular and metabolic health outcomes: A comparative risk assessment. Epidemiol Psychiatr Sci. 2023;32:e8. https:\/\/doi.org\/10.1017\/S2045796023000045.","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"38","key":"973_CR5","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1093\/eurheartj\/ehaf314","volume":"46","author":"S Romeo","year":"2025","unstructured":"Romeo S, Vidal-Puig A, Husain M, Ahima R, Arca M, Bhatt DL, et al. Clinical staging to guide management of metabolic disorders and their sequelae: A European Atherosclerosis Society consensus statement. Eur Heart J. 2025;46(38):3685\u2013713. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf314.","journal-title":"Eur Heart J"},{"issue":"17","key":"973_CR6","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735\u201352. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.169404.","journal-title":"Circulation"},{"issue":"2","key":"973_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-018-0812-z","volume":"20","author":"MG Saklayen","year":"2018","unstructured":"Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):12. https:\/\/doi.org\/10.1007\/s11906-018-0812-z.","journal-title":"Curr Hypertens Rep"},{"issue":"2","key":"973_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/schbul\/sbr148","volume":"39","author":"AJ Mitchell","year":"2013","unstructured":"Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--A systematic review and meta-analysis. Schizophr Bull. 2013;39(2):306\u201318. https:\/\/doi.org\/10.1093\/schbul\/sbr148.","journal-title":"Schizophr Bull"},{"issue":"1","key":"973_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/2045125312464385","volume":"3","author":"E Papanastasiou","year":"2013","unstructured":"Papanastasiou E. The prevalence and mechanisms of metabolic syndrome in schizophrenia: A review. Ther Adv Psychopharmacol. 2013;3(1):33\u201351. https:\/\/doi.org\/10.1177\/2045125312464385.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"7","key":"973_CR10","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1080\/00048670701392841","volume":"41","author":"S Tirupati","year":"2007","unstructured":"Tirupati S, Chua LE. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust N Z J Psychiatry. 2007;41(7):606\u201310. https:\/\/doi.org\/10.1080\/00048670701392841.","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"973_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.31887\/DCNS.2018.20.1\/bpenninx","volume":"20","author":"B Penninx","year":"2018","unstructured":"Penninx B, Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci. 2018;20(1):63\u201373. https:\/\/doi.org\/10.31887\/DCNS.2018.20.1\/bpenninx.","journal-title":"Dialogues Clin Neurosci"},{"issue":"1","key":"973_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02716-8","volume":"14","author":"J Lee","year":"2024","unstructured":"Lee J, Xue X, Au E, McIntyre WB, Asgariroozbehani R, Panganiban K, et al. Glucose dysregulation in antipsychotic-naive first-episode psychosis: In silico exploration of gene expression signatures. Transl Psychiatry. 2024;14(1):19. https:\/\/doi.org\/10.1038\/s41398-023-02716-8.","journal-title":"Transl Psychiatry"},{"key":"973_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101373","volume":"56","author":"V Vaccarino","year":"2025","unstructured":"Vaccarino V, Prescott E, Shah AJ, Bremner JD, Raggi P, Dobiliene O, et al. Mental health disorders and their impact on cardiovascular health disparities. Lancet Reg Health Eur. 2025;56:101373. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101373.","journal-title":"Lancet Reg Health Eur"},{"issue":"4","key":"973_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/met.2008.0070","volume":"7","author":"DM Boudreau","year":"2009","unstructured":"Boudreau DM, Malone DC, Raebel MA, Fishman PA, Nichols GA, Feldstein AC, et al. Health care utilization and costs by metabolic syndrome risk factors. Metab Syndr Relat Disord. 2009;7(4):305\u201314. https:\/\/doi.org\/10.1089\/met.2008.0070.","journal-title":"Metab Syndr Relat Disord"},{"issue":"2","key":"973_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1089\/met.2010.0105","volume":"9","author":"GA Nichols","year":"2011","unstructured":"Nichols GA, Moler EJ. Metabolic syndrome components are associated with future medical costs independent of cardiovascular hospitalization and incident diabetes. Metab Syndr Relat Disord. 2011;9(2):127\u201333. https:\/\/doi.org\/10.1089\/met.2010.0105.","journal-title":"Metab Syndr Relat Disord"},{"key":"973_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euroneuro.2022.10.001","volume":"66","author":"J Simon","year":"2023","unstructured":"Simon J, Wienand D, Park AL, Wippel C, Mayer S, Heilig D, et al. Excess resource use and costs of physical comorbidities in individuals with mental health disorders: a systematic literature review and meta-analysis. Eur Neuropsychopharmacol. 2023;66:14\u201327. https:\/\/doi.org\/10.1016\/j.euroneuro.2022.10.001.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"973_CR17","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1111\/dom.15569","volume":"26","author":"S Milanovic","year":"2024","unstructured":"Milanovic S, Dedic N, Lew R, Burton D, Koblan KS, Camilleri M, et al. TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes. Diabetes Obes Metab. 2024;26(6):2466\u201375. https:\/\/doi.org\/10.1111\/dom.15569.","journal-title":"Diabetes Obes Metab"},{"key":"973_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70110","author":"S Milanovic","year":"2025","unstructured":"Milanovic S, Lew R, Xiong K, Casavant E, Galluppi G, Chen YL, et al. A double-blind study on ulotaront\u2019s impact on weight-related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II. Diabetes Obes Metab. 2025. https:\/\/doi.org\/10.1111\/dom.70110.","journal-title":"Diabetes Obes Metab"},{"key":"973_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70136","author":"S Milanovic","year":"2025","unstructured":"Milanovic S, Lew R, Xiong K, Casavant E, Galluppi G, Chen YL, et al. An open-label study on ulotaront\u2019s effects on insulin-glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I. Diabetes Obes Metab. 2025. https:\/\/doi.org\/10.1111\/dom.70136.","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"973_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19148272","volume":"19","author":"E Jung","year":"2022","unstructured":"Jung E, Kong SY, Ro YS, Ryu HH, Shin SD. Serum cholesterol levels and risk of cardiovascular death: a systematic review and a dose-response meta-analysis of prospective cohort studies. Int J Environ Res Public Health. 2022;19(14):8272. https:\/\/doi.org\/10.3390\/ijerph19148272.","journal-title":"Int J Environ Res Public Health"},{"key":"973_CR21","unstructured":"Harvey R, Jankus DD, Mosley D, Healthcare U. Random assignment of proxy event dates to unexposed individuals in observational studies: an automated technique using SAS\u00ae. Midwest SAS Users Group (MSUG). 2012:16\u20138."},{"issue":"8","key":"973_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","volume":"42","author":"DE Ho","year":"2011","unstructured":"Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1\u201328. https:\/\/doi.org\/10.18637\/jss.v042.i08.","journal-title":"J Stat Softw"},{"issue":"25","key":"973_CR23","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107. https:\/\/doi.org\/10.1002\/sim.3697.","journal-title":"Stat Med"},{"issue":"1","key":"973_CR24","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1080\/13696998.2025.2549653","volume":"28","author":"S Awasthi","year":"2025","unstructured":"Awasthi S, Hadzi Boskovic D, Kapadia S. Association between timing of adjunctive brexpiprazole initiation and healthcare resource use and costs in major depressive disorder. J Med Econ. 2025;28(1):1348\u201356. https:\/\/doi.org\/10.1080\/13696998.2025.2549653.","journal-title":"J Med Econ"},{"key":"973_CR25","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2024","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2024."},{"issue":"10","key":"973_CR26","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.2337\/dc07-0460","volume":"30","author":"LH Curtis","year":"2007","unstructured":"Curtis LH, Hammill BG, Bethel MA, Anstrom KJ, Gottdiener JS, Schulman KA. Costs of the metabolic syndrome in elderly individuals: findings from the Cardiovascular Health Study. Diabetes Care. 2007;30(10):2553\u20138. https:\/\/doi.org\/10.2337\/dc07-0460.","journal-title":"Diabetes Care"},{"key":"973_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15030176","author":"J Sapienza","year":"2025","unstructured":"Sapienza J, Agostoni G, Repaci F, Spangaro M, Comai S, Bosia M. Metabolic syndrome and schizophrenia: adding a piece to the interplay between the kynurenine pathway and inflammation. Metabolites. 2025. https:\/\/doi.org\/10.3390\/metabo15030176.","journal-title":"Metabolites"},{"issue":"4","key":"973_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000512082","volume":"80","author":"M Bosia","year":"2021","unstructured":"Bosia M, Spangaro M, Sapienza J, Martini F, Civardi S, Buonocore M, et al. Cognition in schizophrenia: modeling the interplay between interleukin-1\u03b2 C-511T polymorphism, metabolic syndrome, and sex. Neuropsychobiology. 2021;80(4):321\u201332. https:\/\/doi.org\/10.1159\/000512082.","journal-title":"Neuropsychobiology"},{"key":"973_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1594334","volume":"16","author":"I Moniem","year":"2025","unstructured":"Moniem I, Kafetzopoulos V. Sex differences in schizophrenia: symptomatology, treatment efficacy and adverse effects. Front Psychiatry. 2025;16:1594334. https:\/\/doi.org\/10.3389\/fpsyt.2025.1594334.","journal-title":"Front Psychiatry"},{"key":"973_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2020.105061","volume":"124","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Song X, Guo Y, Lang X, Li Z, Zhang XY. Sex differences in metabolic disorder patterns of first-episode drug-naive patients with schizophrenia. Psychoneuroendocrinology. 2021;124:105061. https:\/\/doi.org\/10.1016\/j.psyneuen.2020.105061.","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"973_CR31","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.123.032625","volume":"13","author":"J Komuro","year":"2024","unstructured":"Komuro J, Kaneko H, Suzuki Y, Okada A, Fujiu K, Takeda N, et al. Sex differences in the relationship between schizophrenia and the development of cardiovascular disease. J Am Heart Assoc. 2024;13(5):e032625. https:\/\/doi.org\/10.1161\/jaha.123.032625.","journal-title":"J Am Heart Assoc"},{"key":"973_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1176\/appi.books.9780890424841","volume-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia: guideline statement summary","author":"American Psychiatric Association","year":"2020","unstructured":"American Psychiatric Association. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia: guideline statement summary. 3rd Edition ed. 2020. p. 5\u20136.","edition":"3rd Edition ed"},{"issue":"6","key":"973_CR33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1089\/met.2023.0003","volume":"21","author":"PS Akinola","year":"2023","unstructured":"Akinola PS, Tardif I, Leclerc J. Antipsychotic-induced metabolic syndrome: a review. Metab Syndr Relat Disord. 2023;21(6):294\u2013305. https:\/\/doi.org\/10.1089\/met.2023.0003.","journal-title":"Metab Syndr Relat Disord"},{"issue":"1","key":"973_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64\u201377. https:\/\/doi.org\/10.1016\/S2215-0366(19)30416-X.","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"973_CR35","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00406-023-01580-3","volume":"273","author":"ED Achtyes","year":"2023","unstructured":"Achtyes ED, Hopkins SC, Dedic N, Dworak H, Zeni C, Koblan K. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2023;273(7):1543\u201356. https:\/\/doi.org\/10.1007\/s00406-023-01580-3.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"973_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaf059","author":"YC Hsu","year":"2025","unstructured":"Hsu YC, Hung TY, Chen YB, Hung KC, Liang CS, Tseng PT, et al. Trajectory of efficacy and safety across Ulotaront dose levels in schizophrenia: a systematic review and dose-response meta-analysis. Int J Neuropsychopharmacol. 2025. https:\/\/doi.org\/10.1093\/ijnp\/pyaf059.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"973_CR37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/med4.70013","volume":"3","author":"JM Hussain","year":"2025","unstructured":"Hussain JM, Arif W, Humayun S, Shoaib N, Khan SM. Xanomeline\u2010trospium chloride (Cobenfy): a new era in managing schizophrenia\u2014comparative effectiveness and economic challenges. Medicine Advances. 2025;3(2):116\u201321. https:\/\/doi.org\/10.1002\/med4.70013.","journal-title":"Medicine Advances"},{"issue":"8","key":"973_CR38","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","volume":"81","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Walling DP, Tamminga CA, Breier A, Zhu H, et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: A randomized clinical trial. JAMA Psychiat. 2024;81(8):749\u201356. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.0785.","journal-title":"JAMA Psychiat"},{"issue":"16","key":"973_CR39","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","volume":"382","author":"KS Koblan","year":"2020","unstructured":"Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382(16):1497\u2013506. https:\/\/doi.org\/10.1056\/NEJMoa1911772.","journal-title":"N Engl J Med"},{"key":"973_CR40","unstructured":"United States Food and Drug Administration (FDA). COBENFY: Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216158s000lbl.pdf. (Accessed Oct 24, 2025). 2024."},{"key":"973_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.scog.2022.100245","volume":"28","author":"F Cuoco","year":"2022","unstructured":"Cuoco F, Agostoni G, Lesmo S, Sapienza J, Buonocore M, Bechi M, et al. Get up! functional mobility and metabolic syndrome in chronic schizophrenia: effects on cognition and quality of life. Schizophr Res Cognit. 2022;28:100245. https:\/\/doi.org\/10.1016\/j.scog.2022.100245.","journal-title":"Schizophr Res Cognit"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00973-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00973-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00973-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:29Z","timestamp":1784819489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00973-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["973"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00973-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Xue Han, Seth C. Hopkins, and Zhen Zhang are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. Shivanshu Awasthi was an employee of Otsuka Pharmaceutical Development & Commercialization, Inc., at the time the study was conducted. Data were obtained from the STATinMED RWD Insights database under a valid and active license agreement, and analyses and publication of findings were conducted in accordance with the terms of such agreement.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is an analysis of deidentified claims data, and therefore no ethical approval was required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}